NCT04478591View on ClinicalTrials.gov

The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis

CompletedOBSERVATIONAL

Enrollment

117

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

April 1, 2021

Study Completion Date

May 1, 2021

Conditions

Multiple Sclerosis

Interventions

OTHER

Questionnaires

All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).

Trial Locations (1)

1007 MB

Amsterdam UMC, location VUmc, Amsterdam

All Listed Sponsors

lead

Amsterdam UMC, location VUmc

OTHER

NCT04478591 - The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter